155 related articles for article (PubMed ID: 21847065)
21. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S; Kim TM; Kim DW; Go H; Keam B; Lee SH; Ku JL; Chung DH; Heo DS
J Thorac Oncol; 2013 Apr; 8(4):415-22. PubMed ID: 23344087
[TBL] [Abstract][Full Text] [Related]
23. EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.
Satoh Y; Matsuo Y; Kuba T; Yamashita K; Sawano M; Tozaka S; Yamazaki H; Sonoda D; Mikubo M; Naito M; Matsui Y; Shiomi K; Yoshida T; Murakumo Y
Virchows Arch; 2020 May; 476(5):753-762. PubMed ID: 31823000
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
25. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ; Mittempergher L; Davidson NM; Bosma A; Willems SM; Horlings HM; de Rink I; Greger L; Hooijer GK; Peters D; Nederlof PM; Hofland I; de Jong J; Wesseling J; Kluin RJ; Brugman W; Kerkhoven R; Nieboer F; Roepman P; Broeks A; Muley TR; Jassem J; Niklinski J; van Zandwijk N; Brazma A; Oshlack A; van den Heuvel M; Bernards R
J Pathol; 2013 Jul; 230(3):270-6. PubMed ID: 23661334
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
27. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.
Kim H; Park E; Kim YJ; Chung JH
Virchows Arch; 2013 May; 462(5):597-9. PubMed ID: 23605565
[No Abstract] [Full Text] [Related]
28. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
29. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
30. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
31. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.
Togashi Y; Mizuuchi H; Kobayashi Y; Hayashi H; Terashima M; Sakai K; Banno E; Mizukami T; Nakamura Y; de Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Ann Oncol; 2015 Aug; 26(8):1800-1. PubMed ID: 26002608
[No Abstract] [Full Text] [Related]
32. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
[No Abstract] [Full Text] [Related]
33. [ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives].
Shen Q; Pan Y; Yu B; Shi S; Liu B; Xu Y; Wang Y; Xia Q; Rao Q; Lu Z; Shi Q; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):164-9. PubMed ID: 26268749
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
[TBL] [Abstract][Full Text] [Related]
35. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
[TBL] [Abstract][Full Text] [Related]
36. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique.
Nicoś M; Krawczyk P; Wojas-Krawczyk K; Bożyk A; Jarosz B; Sawicki M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2017 Dec; 19(12):1447-1453. PubMed ID: 28534101
[TBL] [Abstract][Full Text] [Related]
38. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
39. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
[TBL] [Abstract][Full Text] [Related]
40. The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
Cardarella S; Ortiz TM; Joshi VA; Butaney M; Jackman DM; Kwiatkowski DJ; Yeap BY; Jänne PA; Lindeman NI; Johnson BE
J Thorac Oncol; 2012 Dec; 7(12):1767-1774. PubMed ID: 23154547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
